• The Olink panel provided some directions we wouldn’t have considered previously, and is a very appealing strategy for neuroscience projects hoping to identify novel CSF biomarkers

    • Tom Lanz

    • Principal Scientist, Pfizer Neuroscience

  • We have employed Olink panels in longitudinal deep phenotyping studies of over 5,000 individuals. We have found the data quality and reproducibility to be among the best of the high dimensional data strategies we have used.

    • Professor Leroy Hood

    • Institute for Systems Biology, Seattle

  • In profiling the immune systems of newborn children, the Olink panels allow us to maximize the amount of information extracted from a few microliters of plasma.

    • Assistant Professor Petter Brodin

    • Department of Medicine, Karolinska Institute, Stockholm

  • I am very pleased with the Olink methodology, which has revealed several new biomarkers in the CSF and plasma from patients with multiple sclerosis. It was of particular interest to be able to detect markers in plasma that reflect neuronal damage, including neurofilament light chains

    • Professor Tomas Olsson

    • Center for Molecular Medicine, Karolinska Hospital, Stockholm

  • Olink has developed a very innovative technology that has a simplicity approach to be able to measure large numbers of proteins. That’s a significant breakthrough for investigators to break into a field of diseases that you could not explore without this technology.

    • Professor C.Thomas Caskey

    • Baylor College of Medicine, Houston TX

  • Olink’s immunoassay panels are very useful tools for targeting and discovering protein dynamics in our longitudinal studies, such as the integrative personal omics profile (iPOP)

    • Professor Mike Snyder

    • Department of Genetics, Stanford University

  • We are impressed by the quality of data delivered by the Olink technology with very small sample sizes. The application in the field of precision medicine is extremely promising.

    • Professor Mathias Uhlen

    • Science for Life Laboratory & Royal Institute of Technology (KTH), Stockholm

  • My interest in biomarkers grew in parallel to the growth of Olink. Back in 2014, when I first selected the Olink technology for an important  EU-funded program that I was coordinating, the company had only a handful of employees. Since then, Olink’s growth was amazing. Yet, they still  behave like partners, not simple providers. I have since recommended Olink to many international colleagues.

    • Faiez Zannad

    • Professeur de Thérapeutique-Cardiologie Coordinateur, Centre d’Investigation Clinique Inserm, CHU, Université de Lorraine
Read more about what our customers say about us

Olink news (May 23, 2019)

Now available on-demand: Olink-sponsored webinar with Science/AAAS

“Protein biomarkers and cardiovascular /cardiometabolic disease: Better prediction, deeper understanding” was broadcast on Wednesday, May 22, 2019. The webinar  focused on how protein biomarkers are making an impact in cardiovascular/cardiometabolic medicine, and  featured outstanding presentations by Professor Robert Gerszten, M.D. (Beth Israel Deaconess Medical School, Boston) and Dr. Michiel J. Bom, M.D. (VU University Medical Center Amsterdam). The webinar is now available as an on-demand recording that you can view at your convenience. Sign up for, or learn more about this webinar recording using the link buttons below:

Publications

See all publications

News & Events Highlights

See all

The Olink Community Meets at the Nobel Forum,

View the video and get a flavor of the major international meeting, “Precision Proteomics to Drive Personalized Medicine“, which Olink  arranged at the Nobel Forum in Stockholm on June 19, 2018. This global event brought together leading scientists from both academia and industry to listen to a series of outstanding presentations and to engage in important discussions around the increasing importance of protein biomarkers for the development of more personalized healthcare.